Yeny Acosta-Ampudia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yeny Acosta-Ampudia has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Carolina Ramírez-Santana
Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia
17 shared publications - Diana M. Monsalve
Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia
17 shared publications - Juan-Manuel Anaya
Universidad de la Costa, Barranquilla, Colombia
16 shared publications - Yovana Pacheco
Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia
9 shared publications - Mónica Rodríguez-Jiménez
Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia
7 shared publications Yhojan Rodríguez
Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia
7 shared publications
Latest Publications
- Open Access
- 9 December 2025
- Published by Elsevier in Journal of Translational Autoimmunity
- Vol. 12, 100341
Exploring the immunomodulatory effects of environmental contaminants on autoimmune patients: An in vitro approach
- 9 December 2025
- Published by Elsevier in Journal of Translational Autoimmunity
- Vol. 12, 100341
Open AccessExploring the immunomodulatory effects of environmental contaminants on autoimmune patients: An in vitro approach
- Open Access
- 10 October 2024
- Published by Elsevier in Journal of Translational Autoimmunity
- Vol. 9, 100253
Airborne culprits: A comprehensive review of PM, silica, and TCDD in autoimmune diseases
- 10 October 2024
- Published by Elsevier in Journal of Translational Autoimmunity
- Vol. 9, 100253
Open AccessAirborne culprits: A comprehensive review of PM, silica, and TCDD in autoimmune diseases
- Open Access
- 8 August 2023
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 10, 1215039
Metabolic fingerprinting of systemic sclerosis: a systematic review
Introduction: Systemic sclerosis (SSc) is a chronic autoimmune disease, marked by an unpredictable course, high morbidity, and increased mortality risk that occurs especially in the diffuse and rapidly progressive forms of the disease, characterized by fibrosis of the skin and internal organs and endothelial dysfunction. Recent studies suggest that the identification of altered metabolic pathways may play a key role in understanding the pathophysiology of the disease. Therefore, metabolomics might be pivotal in a better understanding of these pathogenic mechanisms.Methods: Through a systematic review of the literature following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Guidelines (PRISMA), searches were done in the PubMed, EMBASE, Web of Science, and Scopus databases from 2000 to September 2022. Three researchers independently reviewed the literature and extracted the data based on predefined inclusion and exclusion criteria.Results: Of the screened studies, 26 fulfilled the inclusion criteria. A total of 151 metabolites were differentially distributed between SSc patients and healthy controls (HC). The main deregulated metabolites were those derived from amino acids, specifically homocysteine (Hcy), proline, alpha-N-phenylacetyl-L-glutamine, glutamine, asymmetric dimethylarginine (ADMA), citrulline and ornithine, kynurenine (Kyn), and tryptophan (Trp), as well as acylcarnitines associated with long-chain fatty acids and tricarboxylic acids such as citrate and succinate. Additionally, differences in metabolic profiling between SSc subtypes were identified. The diffuse cutaneous systemic sclerosis (dcSSc) subtype showed upregulated amino acid-related pathways involved in fibrosis, endothelial dysfunction, and gut dysbiosis. Lastly, potential biomarkers were evaluated for the diagnosis of SSc, the identification of the dcSSc subtype, pulmonary arterial hypertension, and interstitial lung disease. These potential biomarkers are within amino acids, nucleotides, carboxylic acids, and carbohydrate metabolism.Discussion: The altered metabolite mechanisms identified in this study mostly point to perturbations in amino acid-related pathways, fatty acid beta-oxidation, and in the tricarboxylic acid cycle, possibly associated with inflammation, vascular damage, fibrosis, and gut dysbiosis. Further studies in targeted metabolomics are required to evaluate potential biomarkers for diagnosis, prognosis, and treatment response.
- 8 August 2023
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 10, 1215039
Open AccessMetabolic fingerprinting of systemic sclerosis: a systematic review
Introduction: Systemic sclerosis (SSc) is a chronic autoimmune disease, marked by an unpredictable course, high morbidity, and increased mortality risk that occurs especially in the diffuse and rapidly progressive forms of the disease, characterized by fibrosis of the skin and internal organs and endothelial dysfunction. Recent studies suggest that the identification of altered metabolic pathways may play a key role in understanding the pathophysiology of the disease. Therefore, metabolomics might be pivotal in a better understanding of these pathogenic mechanisms.Methods: Through a systematic review of the literature following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Guidelines (PRISMA), searches were done in the PubMed, EMBASE, Web of Science, and Scopus databases from 2000 to September 2022. Three researchers independently reviewed the literature and extracted the data based on predefined inclusion and exclusion criteria.Results: Of the screened studies, 26 fulfilled the inclusion criteria. A total of 151 metabolites were differentially distributed between SSc patients and healthy controls (HC). The main deregulated metabolites were those derived from amino acids, specifically homocysteine (Hcy), proline, alpha-N-phenylacetyl-L-glutamine, glutamine, asymmetric dimethylarginine (ADMA), citrulline and ornithine, kynurenine (Kyn), and tryptophan (Trp), as well as acylcarnitines associated with long-chain fatty acids and tricarboxylic acids such as citrate and succinate. Additionally, differences in metabolic profiling between SSc subtypes were identified. The diffuse cutaneous systemic sclerosis (dcSSc) subtype showed upregulated amino acid-related pathways involved in fibrosis, endothelial dysfunction, and gut dysbiosis. Lastly, potential biomarkers were evaluated for the diagnosis of SSc, the identification of the dcSSc subtype, pulmonary arterial hypertension, and interstitial lung disease. These potential biomarkers are within amino acids, nucleotides, carboxylic acids, and carbohydrate metabolism.Discussion: The altered metabolite mechanisms identified in this study mostly point to perturbations in amino acid-related pathways, fatty acid beta-oxidation, and in the tricarboxylic acid cycle, possibly associated with inflammation, vascular damage, fibrosis, and gut dysbiosis. Further studies in targeted metabolomics are required to evaluate potential biomarkers for diagnosis, prognosis, and treatment response.
- 22 March 2022
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 226 (4) , 753-754
Reply to Cimolai: Post-COVID syndrome and autoimmunity
To the Editor—The correspondence by Cimolai suggests that the activation of nonspecific polyclonal B cells could be responsible for the presence of autoantibodies after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Viral infections induce transient autoimmune responses with low titers of autoantibodies. However, progression of this immune state to an established autoimmune disease with production of organ- or tissue-specific autoantibodies has been described in multiple infections [ 1]. Some viral infections have been shown to trigger autoimmunity due to mechanisms such as epitope spreading, bystander activation, molecular mimicry, and cryptic epitopes [ 1]. SARS-CoV-2 shares characteristics of other viruses associated with the development of autoimmunity; these include the following: The effect of autoantibodies may partly explain the phenomenon of PCS, in which individuals experience persistent symptoms weeks or months after infection. Evidence indicates that latent autoimmunity may precede the appearance of autoimmune disease several years before clinical manifestations (ie, overt autoimmunity), and several random factors are required for its emergence [ 10]. The transit from latent to overt autoimmunity will depend upon several factors including “the pathogenicity of autoantibodies (ie, affinity, isotype switching, glycosylation, rise in the levels, epitope spreading), the milieu (eg, tertiary lymphoid structures), environmental factors and both epigenetic and genetic characteristics of the individual” [ 11]. Whether PCS is an autolimited or transitory condition is still unknown. Thus, it highlights the critical role of longitudinal studies in PCS to confirm the development or not of overt autoimmunity in the incoming years.
- 22 March 2022
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 226 (4) , 753-754
Reply to Cimolai: Post-COVID syndrome and autoimmunity
To the Editor—The correspondence by Cimolai suggests that the activation of nonspecific polyclonal B cells could be responsible for the presence of autoantibodies after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Viral infections induce transient autoimmune responses with low titers of autoantibodies. However, progression of this immune state to an established autoimmune disease with production of organ- or tissue-specific autoantibodies has been described in multiple infections [ 1]. Some viral infections have been shown to trigger autoimmunity due to mechanisms such as epitope spreading, bystander activation, molecular mimicry, and cryptic epitopes [ 1]. SARS-CoV-2 shares characteristics of other viruses associated with the development of autoimmunity; these include the following: The effect of autoantibodies may partly explain the phenomenon of PCS, in which individuals experience persistent symptoms weeks or months after infection. Evidence indicates that latent autoimmunity may precede the appearance of autoimmune disease several years before clinical manifestations (ie, overt autoimmunity), and several random factors are required for its emergence [ 10]. The transit from latent to overt autoimmunity will depend upon several factors including “the pathogenicity of autoantibodies (ie, affinity, isotype switching, glycosylation, rise in the levels, epitope spreading), the milieu (eg, tertiary lymphoid structures), environmental factors and both epigenetic and genetic characteristics of the individual” [ 11]. Whether PCS is an autolimited or transitory condition is still unknown. Thus, it highlights the critical role of longitudinal studies in PCS to confirm the development or not of overt autoimmunity in the incoming years.
- Open Access
- 1 January 2020
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 79 (1) , e6
Antinuclear autoantibodies: discordance among four different assays
Detection of antinuclear antibodies (ANAs) is of paramount importance for diagnosis and assessment of autoimmune diseases (ADs), but may vary depending on the method used. Therefore, we aimed to compare three different line immunoassays (LIAs) for ANAs testing in order to simultaneously evaluate their concordance with the results obtained by a well known and widely used ELISA. Sera from women with established systemic lupus erythematosus (SLE, n=62) and Sjogren’s syndrome (SS, n=28) were examined. Patients with SLE had an average age of 48.7 years (IQR 36.8–57.0) with a disease duration of 14.8 years (IQR 9.0–18.0). Patients with SS had an average age of 62.1 years (IQR 55.5–71.0) with a duration of disease of 13.1 years (IQR 8.3–17). Table 1 shows the results from the two-by-two comparison for the four techniques. Different levels of agreement were observed among the assays. In general, they were deficient. The analysis showed only one ‘strong’ level of agreement between ELISA and IMTEC-ANA-LIA Maxx for anti-Ro measurement. Out of 39 comparisons, 14 did …
- 1 January 2020
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 79 (1) , e6
Open AccessAntinuclear autoantibodies: discordance among four different assays
Detection of antinuclear antibodies (ANAs) is of paramount importance for diagnosis and assessment of autoimmune diseases (ADs), but may vary depending on the method used. Therefore, we aimed to compare three different line immunoassays (LIAs) for ANAs testing in order to simultaneously evaluate their concordance with the results obtained by a well known and widely used ELISA. Sera from women with established systemic lupus erythematosus (SLE, n=62) and Sjogren’s syndrome (SS, n=28) were examined. Patients with SLE had an average age of 48.7 years (IQR 36.8–57.0) with a disease duration of 14.8 years (IQR 9.0–18.0). Patients with SS had an average age of 62.1 years (IQR 55.5–71.0) with a duration of disease of 13.1 years (IQR 8.3–17). Table 1 shows the results from the two-by-two comparison for the four techniques. Different levels of agreement were observed among the assays. In general, they were deficient. The analysis showed only one ‘strong’ level of agreement between ELISA and IMTEC-ANA-LIA Maxx for anti-Ro measurement. Out of 39 comparisons, 14 did …
- Open Access
- 1 December 2019
- Published by Elsevier in Journal of Translational Autoimmunity
- Vol. 2, 100015
Identifying the culprits in neurological autoimmune diseases
- 1 December 2019
- Published by Elsevier in Journal of Translational Autoimmunity
- Vol. 2, 100015
Open AccessIdentifying the culprits in neurological autoimmune diseases
- 1 September 2019
- Published by Elsevier in Journal of Autoimmunity
- Vol. 103, 102301
Bystander activation and autoimmunity
- 1 September 2019
- Published by Elsevier in Journal of Autoimmunity
- Vol. 103, 102301
Bystander activation and autoimmunity
- Open Access
- 1 March 2019
- Published by Elsevier in Journal of Autoimmunity
- Vol. 98, 24-32
Cluster analysis of autoimmune rheumatic diseases based on autoantibodies. New insights for polyautoimmunity
- 1 March 2019
- Published by Elsevier in Journal of Autoimmunity
- Vol. 98, 24-32
Open AccessCluster analysis of autoimmune rheumatic diseases based on autoantibodies. New insights for polyautoimmunity
- 10 January 2019
- No. 4,p. 15-22
Cytokine imbalance in patients with systemic sclerosis and resilience: the key role of interleukin-6.
Resilience, the ability to respond positively to adverse events, may be influenced by long-term stressors and autoimmune/inflammatory conditions such as systemic sclerosis (SSc). Since the immune system plays a role in the development of resilience, we aimed to evaluate the relationship between a panel of cytokines and resilience in patients with SSc. Thirty-five consecutive women with established SSc were involved in this exploratory study. Clinical characteristics, including severity of symptoms and resilience, a panel of 15 serum cytokines and 17 autoantibodies were assessed simultaneously. Multivariate methods were used to analyse the data. Interleukin-6 (IL-6) levels were associated with severity of symptoms (β=1.8395, p=0.04), and low resilience scores (β= -0.581120, p=0.02). Furthermore, resilience was not associated with clinical manifestations nor polyautoimmunity. Cytokine levels did not significantly differ between groups based on regular physical activity. The results highlight the importance of IL-6 as a key mediator in the altered cytokine network of SSc.
- 10 January 2019
- No. 4,p. 15-22
Cytokine imbalance in patients with systemic sclerosis and resilience: the key role of interleukin-6.
Resilience, the ability to respond positively to adverse events, may be influenced by long-term stressors and autoimmune/inflammatory conditions such as systemic sclerosis (SSc). Since the immune system plays a role in the development of resilience, we aimed to evaluate the relationship between a panel of cytokines and resilience in patients with SSc. Thirty-five consecutive women with established SSc were involved in this exploratory study. Clinical characteristics, including severity of symptoms and resilience, a panel of 15 serum cytokines and 17 autoantibodies were assessed simultaneously. Multivariate methods were used to analyse the data. Interleukin-6 (IL-6) levels were associated with severity of symptoms (β=1.8395, p=0.04), and low resilience scores (β= -0.581120, p=0.02). Furthermore, resilience was not associated with clinical manifestations nor polyautoimmunity. Cytokine levels did not significantly differ between groups based on regular physical activity. The results highlight the importance of IL-6 as a key mediator in the altered cytokine network of SSc.
- Open Access
- 26 September 2018
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 7 (1) , 1-11
Mayaro: an emerging viral threat?
Mayaro virus (MAYV), an enveloped RNA virus, belongs to the Togaviridae family and Alphavirus genus. This arthropod-borne virus (Arbovirus) is similar to Chikungunya (CHIKV), Dengue (DENV), and Zik...
- 26 September 2018
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 7 (1) , 1-11
Open AccessMayaro: an emerging viral threat?
Mayaro virus (MAYV), an enveloped RNA virus, belongs to the Togaviridae family and Alphavirus genus. This arthropod-borne virus (Arbovirus) is similar to Chikungunya (CHIKV), Dengue (DENV), and Zik...